Chembio (NASDAQ:CEMI) capped 2012 with another very strong quarter as Q4 set a new all-time revenue record, which helped push full-year revenue up 32%. Q4 was cash flow positive (ex. changes in working cap), and CEMI's balance sheet remains solid.
All the major product segments posted year-over-year sales gains in Q4 as well as for the full fiscal year. Dual Path Platform (DPP) product sales to the Oswaldo Cruz Foundation (or FIOCRUZ, Brazil's public health organization) remained on a tear, up 70% in Q4 and +137% for the year. Perhaps even a bigger highlight (and a bigger percent upside surprise to our Q4 modeled revenue) in terms of revenue in Q4 was rebounded strength in lateral flow sales -- both domestically and internationally. Management indicated during the call that market share gains by Alere, combined with the potential benefits of recent recommendations by the U.S. Preventative Services Task Force (USPSTF) relative to routine HIV testing, bode well for continued revenue growth of the domestic lateral flow products.
We had already baked at least some of that into our model. However, more of a wildcard in terms of forecasting out sales of the lateral flow products has been to international markets -- sales of which dipped 17% in 2011 and were up just 2% in 2012. Management noted during the call that they've recently focused more efforts on jump-starting growth in this business, including expanding distribution, which has started paying dividends -- specifically pointing to a recent large order to a U.N. agency related to a national testing program. Expectations are that both domestic and international lateral flow sales will continue to grow.
On the operational side, the major highlight during Q4 was the announcement in December that the FDA approved CEMI's DPP HIV 1/2 test for blood and oral fluid samples. The next step will be to obtain CLIA waiver to allow the test to be sold to the POC market. CEMI expects to have the related trials complete and the CLIA waiver package submitted around the middle of 2013. If all goes to plan the test will roll out in late 2013 or early 2014, supported by a small internal sales force (targeting the public health market) as well as via distributors (targeting hospitals and physician offices).
And as we detail below, CEMI continues to make progress on several of its pipeline products, including the high-potential DPP Syphilis Screen and Confirm test as well as the DPP HIV/Syphilis test.
Q4/Full-Year 2012 Financial Results
2012 revenue of $25.6 million was up 32% and was an all-time record. About 94% of the $6.2 million increase in revenue from 2011 to 2012 came from DPP product sales to FIOCRUZ. As we've noted in the past, as the DPP product portfolio represents a major catalyst to CEMI's potential mid- to long-term growth (in the U.S. and other countries), the recent strong performance of these products is an obvious positive. 2012 GAAP and adjusted EPS were $0.11 and $0.17, compared to $0.74 and $0.13 in 2011.
Q4 revenue of $7.86 million (+27%) beat our $7.25 million number by about 9%, with both domestic and international lateral flow as well as DPP product sales beating our estimates. Meanwhile, non-product revenue (R&D contracts, grants, milestones) of $458k was about dead-on with our number.
Sales of the company's lateral flow products to Alere increased 4% yoy and 59% sequentially to $1.9 million compared to our $1.5 million estimate. As noted, market share gains by Alere have recently helped buoy sales which, along with new HIV testing recommendations should provide a catalyst to further growth. International lateral flow sales were up 12% yoy and +162% sequentially to $2.6 million compared to our $2.5 million estimate. International sales benefitted from a ~$3 million order, about $1.8 million of which was booked during the quarter (the remainder should hit Q1 2013). The order appears to be a direct result of CEMI's renewed efforts on growing this business which includes expanding their distribution base. DPP sales remained very strong in Q4, up 70% yoy, up 11% sequentially and 9% better than our $2.6 million estimate. This level of DPP sales may not repeat in 2013, however.
As a reminder, the majority of DPP sales to-date have been to FIOCRUZ related to a technology transfer agreement for five DPP tests (HIV, HIV confirm, syphilis, leishmaniasis, and leptospirosis) . Per terms of the agreement, FIOCRUZ is obligated to purchase a total of $23MM worth (each test has a minimum purchase amount assigned) before the technology is transferred to FIOCRUZ --- at that point FIOCRUZ can take ownership for the Brazil market and CEMI will receive a royalty on sales. FIOCRUZ may purchase significantly more than the $23 million and substantially exceeded the minimums under an earlier tech transfer agreement.
Through the end of 2012 we estimate FIOCRUZ had purchased ~$14+ million. As we noted in prior updates, we had expected FIOCRUZ to meet its minimum purchase quota around the end of 2013 -- which remains our assumption, but not take ownership of manufacturing until 2015. CEMI notes in their recent 10-K that FIOCRUZ recently notified them that scale-up in Brazil's national HIV and syphilis testing programs is going slower than had been expected. CEMI notes that this will likely result in lower DPP related revenue from FIOCRUZ in 2013 compared to 2012 (2012 FIOCRUZ DPP revenue was ~$10MM). As such we have since trimmed our FIOCRUZ related revenue contribution for 2013.
Q4 Operating expenses were about 6% higher than our numbers but as a percentage of revenue (31% A vs. 32% E) were slightly better than our estimate.
We use adjusted net income and EPS for consistency purposes. As a reminder, in Q4 2011 CEMI took a non-cash gain of $5.16 million to income from the reversal of deferred tax asset as they expected to generate positive pre-tax income from that point forward. Their GAAP income tax rate of ~39.7% is 90% non-cash until they exhaust (which, based on our current model, will occur sometime in 2015) their entire deferred tax asset which stood at $4.2 million at the end of 2012. Q4 adjusted net income and EPS of approximately $697k and $0.08 were just about dead-on with our $682k and $0.08 estimates.
Excluding changes in working capital (which included a spike in A/R related to the large international order and an increase in inventory), cash from operations was an inflow of $929k in Q4 and $2.3 million for full-year 2012. Chembio exited 2012 with $2.95 million in cash and equivalents and relatively immaterial debt.
DPP HIV, U.S.
FDA approval for all sample types (oral fluid, whole blood, serum, and plasma) came in December. Studies to support CLIA waiver are expected to start in March and an FDA submission to happen by July. CLIA waiver and launch could happen by late 2013 or early 2014.
In clinical studies the product has shown to have superior performance to OraSure's oral fluid test as well as other rapid HIV tests using blood samples. CEMI's DPP HIV test's FDA approved label includes claims of sensitivity/specificity on oral fluid and whole blood of 98.9%/99.9% and 99.9%/100%, respectively. Oral fluid sensitivity was 100% among patients not on anti-retroviral medication.
Certain advantages of CEMI's DPP HIV product, including superior performance, long shelf-life, broader label including approved for patients 2 years and older (vs. 13 years and older with competitors'), and earlier detection on serum samples should bode well for it competing against OraSure's (NASDAQ:OSUR) oral fluid rapid HIV test. CEMI's plan for selling the test includes detailing to the public health sector with its own (very small) sales force as well as through distributors to target hospitals and physicians' offices. We model the test to launch in early 2014 (which may be slightly more conservative than management's expectations).
DPP Syphilis Screen and Confirm
Syphilis Screen and Confirm (treponemal/non-treponemal) test was CE Marked in Europe in early October 2011. CEMI noted that during Q2 they established distribution for the test in the U.K.
Relative to the road to FDA approval, CEMI now believes the data they have, which includes data from a multi-site study done in China with over 3,000 samples and published late last year online in the journal Clinical Infectious Diseases provides significant support to reinitiate clinical trials in their quest to gain 510(k) clearance from the FDA. CEMI submitted the additional data to the FDA and the regulator responded in February. CEMI will meet with the agency this month to go over some questions related to the FDA's response. CEMI noted on the call that they have already identified 3 study sites and drafted contracts related to the studies -- clearly indicating that they expect the FDA to give the green light to run the studies to support 510(k) clearance. CEMI hopes to commence the studies in April or May, submit the 510(k) application by end of Q3 and have FDA clearance by mid-2014.
We think CEMI's DPP POC syphilis screen and confirm test could have significant appeal given that it would be the first POC treponemal/non-treponemal test on the market with accuracy competitive to lab tests. The test would potentially draw significant demand overseas as well, particularly in developing countries where infectious diseases (including HIV and syphilis) can be overly problematic. Our model assume the test launches in the U.S. in late 2014.
Chembio is now even more focused on development of a competitive DPP hepatitis C test following the recently released recommendation by the CDC that all Americans ages 45-65 be tested for the virus as well as independent data published in the Journal of Virology, which indicated relatively high accuracy of CEMI's HCV test.
Chembio efforts relative to DPP HCV have most recently focused on improving upon accuracy and competitiveness compared to rapid HCV tests already on the market. Chembio is now looking at including antigen detection on top of antibody detection. All the rapid HCV tests currently on the U.S. market are all antibody tests, which can fail to detect the virus especially in the early stages of the disease when antibody presence is low.
In Q3 CEMI completed an initial feasibility study on proprietary antigens and had been awaiting additional proprietary materials to further improve the performance of their initial DPP HCV test (the initial test was used in the study cited in The Journal of Virology article) compared to competitive products. CEMI has since received these and is continuing with development of the test.
Assuming development continues with positive results, CEMI believes clinical trials could commence in early 2014. We note that we had removed a DPP HCV test from our model in early 2011 when it looked like CEMI may abandon the program. While we still do not model the test, we will revisit this depending on how things progress.
DPP Syphilis/HIV combo
CEMI still looking at opportunities in international markets for the test including donor-funded pre-natal testing programs in emerging markets aimed at mother to child transmission. CEMI has submitted the test to the CDC and the World Health Organization accepted it for pre-qualification in their global procurement scheme.
Relative to the FDA approval pathway, CEMI hopes to submit a guidance request to the FDA in the near-term. Given that the HIV portion of this test is the same as the one approved by the FDA in December, the expectation is that CEMI can use the data from the syphilis studies (to begin April/May) to support the syphilis part of the test.
CEMI had been waiting for FDA's decision on OraSure's OTC HIV test before going full-bore on their OTC HIV program. In early July the FDA approved OraSure's OraQuick over-the-counter rapid HIV. The test, which uses an oral swab (saliva) as the sample and is basically identical to the test sold to the clinical market, is the first HIV test to be approved for home use.
FDA's decision essentially green-lighted CEMI's move to proceed with their home-use HIV test. Chembio continues to evaluate the OTC market size and opportunity and will proceed cautiously before committing to expensive clinical trials to gain OTC approval of their Sure Check rapid HIV test, which is already FDA approved for the clinical market. The design, scope, size and cost of CEMI's OTC program are yet to be nailed down but Chembio has almost certainly reviewed the path that OraSure already paved and can use that as (at least) a rough guide for what to expect to gain FDA approval. They will also have the advantage of seeing exactly how well OSUR's test sells and the demand for OTC HIV testing.
Chembio expects to submit an IDE to the FDA in the near-term. Assuming it's granted (which we expect it to be), CEMI can then work towards their clinical trials. It's difficult to gauge the scope of the development program that CEMI will need to follow but for reference, OraSure enrolled ~5,800 people in its final clinical trial. We think it's probably safe to assume that this will be a multi-year and multi-million-dollar endeavor. As it is now, we assume FDA approval will not happen prior to the out-year (2015) of our model but our model does now include (best-guess) development/regulatory expenses beginning in 2013 related to the OTC HIV program. CEMI may also look to partner -- we will update our assumptions as necessary. If, however, CEMI determines that the market opportunity does not warrant an investment in pursuing OTC approval, we will update our model accordingly.
We think, if and when Chembio gets regulatory approval for and launches their OTC HIV test, it can be very competitive to OraSure's OTC test, particularly on performance. We also note that FDA approved OSUR's OraQuick OTC test, despite seemingly low (~92%) sensitivity when administered by consumers (as opposed to by doctors). This low sensitivity is likely in CEMI's sights and we think that if they can show better performance, that would be a very compelling message when the product rolls out. We do note that OSUR's test uses an oral swab as the sample, whereby CEMI's current Sure Check uses blood. Assuming equal performance, oral swab would be considered an advantage from an ease and comfort of administration basis -- but this advantage could be potentially largely negated with superior performance. For obvious reasons, FDA and physicians (and consumers) have serious concerns relative to accuracy of HIV home tests -- oral swab versus blood sampling may be a relatively benign convenience gap if CEMI's test shows greater accuracy.
We now look for 2013 revenue of $26.6 million, which is adjusted down from $29.4 million prior to Q4 results -- largely due to trimming our FIOCRUZ related contribution (as detailed above). While we now model DPP sales to contract in 2013, total revenue should still grow given expected continued strength in domestic lateral flow sales and what we think could be a better than previously anticipated showing from international lateral flow sales.
As we have previously, we continue to use the assumption that FIOCRUZ will meet its purchasing quota in 2013, although we have absolutely no insight into when to expect that FIOCRUZ will begin to manufacture the products. We also continue to use beginning of 2015 as a placeholder for this to occur. Our model reflects this and is the reason we have 2015 revenue falling ~7% -- we also model some trimming in expenses, which somewhat mutes the impact to the bottom line.
We model adjusted net income and EPS of $2.1 million and $0.25 in 2013, compared to $1.4 million and $0.17 in 2012.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Business relationship disclosure: I work as a Consultant Analyst for Zacks Investment Research. The article is written by me and is 100% my opinion. I receive compensation from Zacks for writing equity research reports and providing valuation analysis on this company’s stock and expect to do so in the future. Zacks receives compensation from the company. Please see the Zacks Disclaimer for further information: http://scr.zacks.com/Disclaimer/default.aspx